Chronic Myeloid Leukemia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Chronic Myeloid Leukemia Advisor - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Chronic Myeloid Leukemia Advisor 
Cancer Therapy Advisor
Approval was based on results from the randomized phase 3 BFORE trial, which showed a higher MMR rate in patients treated with bosutinib than in those treated with imatinib. The US Food and Drug Administration approved bosutinib, a second-generation ...
Chronic Myelogenous Leukemia Drug Gains Accelerated Approval Specialty Pharmacy Times
FDA expands approval of Bosulif for chronic myelogenous leukemia Healio
FDA OKs Pfizer's Bosulif For Treatment Of Chronic Myelogenous Leukemia Pharmaceutical Processing
Targeted Oncology  -Monthly Prescribing Reference  -Nasdaq 
all 9 news articles » 


Could Switching to Interferon Avoid an Abnormal Ovarian Response in CML? - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Could Switching to Interferon Avoid an Abnormal Ovarian Response in CML? 
Cancer Therapy Advisor
Switching from a tyrosine kinase inhibitor (TKI) to interferon-alfa (IFN-a) is an option for patients with chronic myeloid leukemia (CML) planning to undergo ovarian stimulation to avoid a potential irregular ovarian response, according to a case ...

 


Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute ... - Dove Medical Press



Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute ... 
Dove Medical Press
Abstract: Ponatinib, a third-generation tyrosine kinase inhibitor that inhibits BCR/ABL independent of the mutation status, is currently approved for the treatment of patients with chronic myeloid leukemia or acute lymphoblastic leukemia that are ...

 


Forecast on Chronic Myelogenous Leukemia Treatment Market for the Period 2017 - 2026 - Digital Journal



Forecast on Chronic Myelogenous Leukemia Treatment Market for the Period 2017 - 2026 
Digital Journal
Albany, NY -- (SBWIRE) -- 01/17/2018 -- Majorly, chronic myelogenous leukemia (CML) occurs in adults, however, it sometimes occurs in children as well. However, targeted drugs called Tyrosine-Kinase Inhibitors (TKIs) have been effective in providing ...

and more » 


Leukemia survivors pen open letters to Texas guard Andrew Jones - Hookem.com



Hookem.com
 
Leukemia survivors pen open letters to Texas guard Andrew Jones 
Hookem.com
... Jones had been diagnosed with leukemia. To contribute to that fund, click here. This week, Nick Paquette and Leah Vann pitched in with the kind of support that can't be measured in dollars and cents: stories of survival. Advertisement. RELATED ...
Texas Longhorns College Basketball - Texas News, Scores, Stats, Rumors & More - ESPN - ESPN.com ESPN.com
Texas Tech Red Raiders College Basketball - Texas Tech News, Scores, Stats, Rumors & More - ESPN - ESPN.com ESPN.com

all 94 news articles » 


CML: Rationale for Mutation Testing and TKI Therapy - Targeted Oncology



Targeted Oncology
 
CML: Rationale for Mutation Testing and TKI Therapy 
Targeted Oncology
Mutation testing may be more important in advanced-disease patients, because the frequency of mutations is higher, and other pH-positive leukemia settings like pH-positive ALL, for example. In chronic CML, again, a lost milestone, or clearly a missed ...

and more » 


FDA Grants Accelerated Approval to Chronic Myelogenous ... - Pharmacy Times



Cancer Network
 
FDA Grants Accelerated Approval to Chronic Myelogenous ... 
Pharmacy Times
Officials with the FDA granted accelerated approval to bosutinib (Bosulif) for the treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The approval was based on ...
FDA Approves New Frontline Drug for Chronic-Phase CML | Cancer ... Cancer Network

all 2 news articles » 


Patients, Payers, Prosecutors, and the Role of the Copay - Bloomberg Big Law Business



Bloomberg Big Law Business
 
Patients, Payers, Prosecutors, and the Role of the Copay 
Bloomberg Big Law Business
For example, a study of patients newly diagnosed with chronic myeloid leukemia found ?significantly lower fill rates and significantly longer time to initiation of [treatment] among beneficiaries . . . who were responsible for high out-of-pocket costs ...

 


The Deciding Factors for CML Treatment - Targeted Oncology - Targeted Oncology



Targeted Oncology
 
The Deciding Factors for CML Treatment - Targeted Oncology 
Targeted Oncology
In this case-based interview, Michael J. Mauro, MD, provides an overview on the therapeutic management of a younger patient with relapsed chronic myeloid leukemia.

and more » 


An open letter to NBA prospect Andrew Jones from another player ... - Yahoo Sports



Yahoo Sports
 
An open letter to NBA prospect Andrew Jones from another player ... 
Yahoo Sports
Nick Paquette, a guard at Division III SUNY New Paltz, hopes his story provides Texas star Andrew Jones with strength, inspiration and hope.

and more »